文献速递浆细胞疾病

维奈克拉或安慰剂联合硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤(BELLINI):随机3期研究的最终总生存结果

Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study.
PubMed 文献 · Lancet Haematol · 2025-06-27

BELLINI 3期研究纳入291例复发或难治性多发性骨髓瘤患者,随机接受维奈克拉或安慰剂联合硼替佐米和地塞米松。中位随访45.6个月,中位总生存两组均未达到(HR 1.19,95%CI 0.80-1.77;P=0.39),中位无进展生存维奈克拉组23.4个月 vs 安慰剂组11.4个月(HR 0.58,95%CI 0.43-0.78;P=0.00026)。最终分析显示总生存 favoring 安慰剂,无进展生存 favoring 维奈克拉,作者认为一般复发或难治性多发性骨髓瘤人群应避免使用维奈克拉。

要点

  • 中位随访45.6个月,中位总生存两组均未达到,HR 1.19(95%CI 0.80-1.77;P=0.39)。
  • 中位无进展生存维奈克拉组23.4个月 vs 安慰剂组11.4个月,HR 0.58(95%CI 0.43-0.78;P=0.00026)。
  • 作者结论:一般复发或难治性多发性骨髓瘤人群应避免使用维奈克拉。

核心结论

  • 最终总生存分析显示总生存 favoring 安慰剂而非维奈克拉,无进展生存 favoring 维奈克拉而非安慰剂,作者认为一般复发或难治性多发性骨髓瘤人群应避免使用维奈克拉。

研究设计与样本

  • 随机、双盲、多中心3期BELLINI研究,纳入18岁及以上、ECOG体能状态≤2、既往1-3线治疗的复发或难治性多发性骨髓瘤患者,来自16个国家90家医院。
  • 患者按2:1中央随机分配至维奈克拉组(n=194)或安慰剂组(n=97),按既往蛋白酶体抑制剂暴露和既往治疗线数分层。
  • 维奈克拉800 mg口服每日一次或安慰剂,联合硼替佐米1.3 mg/m2皮下或静脉注射及地塞米松20 mg口服,21天为一周期共8个初始周期,之后35天为一周期直至停药。

主要发现

  • 中位随访45.6个月(IQR 43.6-48.3),中位总生存维奈克拉组未达到(NR,95%CI 44.4-不可估计)vs 安慰剂组未达到(NR,95%CI 44.0-不可估计),HR 1.19(95%CI 0.80-1.77;P=0.39)。
  • 中位无进展生存维奈克拉组23.4个月(95%CI 16.2-26.4)vs 安慰剂组11.4个月(95%CI 9.5-14.6),HR 0.58(95%CI 0.43-0.78;P=0.00026)。
  • 最常见的3级或4级不良事件为血小板减少(维奈克拉组51/193例[26%] vs 安慰剂组38/96例[40%])和中性粒细胞减少(维奈克拉组58/193例[30%] vs 安慰剂组8/96例[8%])。
  • 治疗相关不良事件导致死亡:维奈克拉组4/193例(2%)(2例肺炎,1例死亡,1例多器官功能障碍综合征和感染性休克),安慰剂组无。

关键数值与推荐

  • 主要终点为独立评审委员会评估的意向治疗人群无进展生存;本分析报告意向治疗人群的总生存和研究者评估的无进展生存。
  • 安全性分析在至少接受一剂研究药物的患者中进行。

临床怎么用

  • 作者结论指出,维奈克拉使用应在一般复发或难治性多发性骨髓瘤人群中避免。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase 3 BELLINI primary endpoint was met, showing superior progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma as assessed by an independent review committee. However, venetoclax showed increased early mortality. Here, we report the final overall survival analysis. METHODS: The randomised, double-blind, multicentre, phase 3 BELLINI study enrolled patients aged 18 years or older with relapsed or refractory multiple myeloma, Eastern Cooperative Oncology Group performance status of 2 or less, and one to three previous therapies, across 90 hospitals in 16 countries. Eligible patients were centrally randomly assigned (2:1, stratified by previous proteasome inhibitor exposure and number of previous lines of therapies) via interactive response technology system (block size 3) to once-daily venetoclax (800 mg orally) or placebo with bortezomib (1·3 mg/m2 subcutaneously or intravenously) and dexamethasone (20 mg orally), administered in 21-day cycles for initial eight cycles, followed by 35-day cycles until discontinuation. The primary endpoint was progression-free survival as assessed by an independent review committee in the intention-to-treat population; this analysis reports overall survival and investigator-assessed progression-free survival in the intention-to-treat population. Safety analyses were done in patients who received at least one dose of the study drug. This study is registered with ClinicalTrials.gov (NCT02755597) and is completed. FINDINGS: From July 19, 2016, to Oct 31, 2017, 291 patients were assigned to venetoclax (n=194) or placebo (n=97); 33 patients (28 in the venetoclax group and five in the placebo group) remained on treatment at the time of this analysis. Of the 291 patients, 152 (52%) were men and 139 (48%) were women. 87 (30%) of 291 patients were Asian, 12 (4%) were Black or African American, 190 (65%) were White, and 32 (11%) were Hispanic or Latino. At 45·6 months (IQR 43·6-48·3) median follow-up, median overall survival was not reached in the venetoclax group (not reached [NR] [95% CI 44·4-not estimable]) or in the placebo group (NR [95% CI 44·0-not estimable]; HR 1·19 [95% CI 0·80-1·77]); p=0·39). Median progression-free survival was 23·4 months (95% CI 16·2-26·4) with venetoclax versus 11·4 months (95% CI 9·5-14·6) with placebo (HR 0·58 [95% CI 0·43-0·78]; p=0·00026). The most common grade 3 or 4 adverse events were thrombocytopenia (51 [26%] of 193 in the venetoclax group vs 38 [40%] of 96 in the placebo group]) and neutropenia (58 [30%] of 193 vs eight [8%] of 96 patients). Treatment-related adverse events led to death in four (2%) of 193 patients in the venetoclax group (two patients with pneumonia, one with death, and one with both multiple organ dysfunction syndrome and septic shock) and none in the placebo group. INTERPRETATION: Final overall survival analysis in the BELLINI study showed overall survival favouring placebo over venetoclax and progression-free survival favouring venetoclax over placebo, indicating venetoclax usage should be avoided in the general relapsed or refractory multiple myeloma population. FUNDING: AbbVie and Genentech.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study. Lancet Haematol. 2025. PMID: 40587991. doi:10.1016/S2352-3026(25)00139-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。